Literature DB >> 29168695

Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.

Rupa R Patel1, Rachel Presti1, Laura C Harrison1, William G Powderly1, Philip A Chan2.   

Abstract

Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29168695      PMCID： PMC6003884          DOI： 10.3851/IMP3208

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  17 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 2.  Geographic and ethnic disparities in osteoporotic fractures.

Authors:  Jane A Cauley; Didier Chalhoub; Ahmed M Kassem; Ghada El-Hajj Fuleihan
Journal:  Nat Rev Endocrinol       Date:  2014-04-22       Impact factor: 43.330

3.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Authors:  Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister
Journal:  Lancet       Date:  2015-04-15       Impact factor: 79.321

4.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

5.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.

Authors:  Ighovwerha Ofotokun; Kehmia Titanji; Cecile D Lahiri; Aswani Vunnava; Antonina Foster; Sara E Sanford; Anandi N Sheth; Jeffrey L Lennox; Andrea Knezevic; Laura Ward; Kirk A Easley; Philip Powers; M Neale Weitzmann
Journal:  Clin Infect Dis       Date:  2016-05-18       Impact factor: 9.079

8.  Hip fractures in the elderly: a world-wide projection.

Authors:  C Cooper; G Campion; L J Melton
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

9.  Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.

Authors:  Albert Y Liu; Eric Vittinghoff; Deborah E Sellmeyer; Risha Irvin; Kathleen Mulligan; Kenneth Mayer; Melanie Thompson; Robert Grant; Sonal Pathak; Brandon O'Hara; Roman Gvetadze; Kata Chillag; Lisa Grohskopf; Susan P Buchbinder
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

10.  Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.

Authors:  Brenda G Mirembe; Clifton W Kelly; Nyaradzo Mgodi; Susan Greenspan; James Y Dai; Ashley Mayo; Jeanna Piper; Carolyne A Akello; Flavia M Kiweewa; Tsitsi Magure; Clemensia Nakabiito; Jeanne M Marrazzo; Z Mike Chirenje; Sharon A Riddler
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.